| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 2751.8 | 2139.9 | 2754.1 |
| Other income | 46.1 | 43.2 | 42.0 |
| Total income | 2797.8 | 2183.1 | 2796.1 |
| Profit before exceptional items & tax | 218.8 | -52.8 | 272.8 |
| Exceptional items | -175.8 | -41.1 | 0.0 |
| Profit before tax | 43.0 | -93.9 | 272.8 |
| Net profit | -8.8 | -136.2 | 153.5 |
| Operating margin | 1.5% | -4.3% | 9.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | -0.10% |
|---|
BSE results filing, NSE: PPLPHARMA. Figures extracted from the filing.
Piramal Pharma Ltd: key numbers
- Share price
- ₹202.68
- Market cap
- ₹26,984 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -86.0×Sector 47.4×
- Promoter holding
- 34.80%-0.06% QoQ
- FII holding
- 12.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Piramal Pharma Ltd
All →Piramal Pharma Other Announcement
Piramal Pharma Limited informed exchanges that Niche99 has independently assigned it an ESG rating of 67.1 (ESG Band: Leader), without any company engagement.
Piramal Pharma Business Update
Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.
Piramal Pharma Other Announcement
Piramal Pharma Limited received an improved ESG rating of 65 from NSE Sustainability Ratings and Analytics. The rating was assigned voluntarily based on public disclosures.
Piramal Pharma Share Pledge
Deutsche Bank AG, acting as security agent, has disclosed the re-creation of a pledge over 98.4 million shares of Piramal Pharma Limited by the borrower.
Piramal Pharma Business Update
Piramal Pharma Limited released its Sustainability Report for FY2025-26, detailing the company's ESG performance across key pillars, including business resilience and operational sustainability.
Piramal Pharma Merger & Restructuring Worth ₹76 Cr
Piramal Pharma acquired an additional 40.67% stake in Yapan Bio for ₹76 Crore. This transaction increases its total holding to 74%, making Yapan Bio a subsidiary.
- Value
- ₹76.00 Cr